A tautomeric ligand enables directed C‒H hydroxylation with molecular oxygen
作者:Zhen Li、Zhen Wang、Nikita Chekshin、Shaoqun Qian、Jennifer X. Qiao、Peter T. Cheng、Kap-Sun Yeung、William R. Ewing、Jin-Quan Yu
DOI:10.1126/science.abg2362
日期:2021.6.25
challenging when oxygen is used as the oxidant. Here, we report a palladium complex bearing a bidentate pyridine/pyridone ligand that efficiently catalyzes this reaction at ring positions adjacent to carboxylic acids. Infrared, x-ray, and computational analysis support a possible role of ligand tautomerization from mono-anionic (L,X) to neutral (L,L) coordination in the catalytic cycle of aerobic carbon–hydrogen
NOVEL BI- AND TRI-CYCLIC AZA COMPOUNDS AND THEIR USES
申请人:Georgetown University
公开号:EP1102751A1
公开(公告)日:2001-05-30
EP1102751A4
申请人:——
公开号:EP1102751A4
公开(公告)日:2005-06-22
US6150376A
申请人:——
公开号:US6150376A
公开(公告)日:2000-11-21
[EN] NOVEL BI- AND TRI-CYCLIC AZA COMPOUNDS AND THEIR USES<br/>[FR] NOUVEAUX COMPOSES AZA BI- ET TRICYCLIQUES ET LEURS UTILISATIONS
申请人:UNIV GEORGETOWN
公开号:WO2000007994A1
公开(公告)日:2000-02-17
The present invention provides tropane-derived monoamine neurotransmitter re-uptake inhibitors which predictably exhibit selectivity for either the serotonin or dopamine transporter, pharmaceutical compositions thereof and methods for their use. The serotonin-selective re-uptake inhibitors are particularly useful for treating neurological disorders associated with the serotonergic neural system of the brain, such as depression, with significantly reduced side-effects. The dopamine-selective re-uptake inhibitors are particularly useful for treating disorders associated with dopamine re-uptake and/or acetylcholine release.